Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation.

Singh PK, Deorukhkar AA, Venkatesulu BP, Li X, Tailor R, Bomalaski JS, Krishnan S.

Mol Cancer Ther. 2019 Aug 8. doi: 10.1158/1535-7163.MCT-18-0708. [Epub ahead of print]

PMID:
31395686
2.

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.

Chalishazar MD, Wait SJ, Huang F, Ireland AS, Mukhopadhyay A, Lee Y, Schuman SS, Guthrie MR, Berrett KC, Vahrenkamp JM, Hu Z, Kudla M, Modzelewska K, Wang G, Ingolia NT, Gertz J, Lum DH, Cosulich SC, Bomalaski JS, DeBerardinis RJ, Oliver TG.

Clin Cancer Res. 2019 Aug 15;25(16):5107-5121. doi: 10.1158/1078-0432.CCR-18-4140. Epub 2019 Jun 4.

PMID:
31164374
3.

A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.

Hall PE, Lewis R, Syed N, Shaffer R, Evanson J, Ellis S, Williams M, Feng X, Johnston A, Thomson JA, Harris FP, Jena R, Matys T, Jefferies S, Smith K, Wu BW, Bomalaski JS, Crook T, O'Neill K, Paraskevopoulos D, Khadeir RS, Sheaff M, Pacey S, Plowman PN, Szlosarek PW.

Clin Cancer Res. 2019 May 1;25(9):2708-2716. doi: 10.1158/1078-0432.CCR-18-3729. Epub 2019 Feb 22.

PMID:
30796035
4.

Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.

Przystal JM, Hajji N, Khozoie C, Renziehausen A, Zeng Q, Abaitua F, Hajitou A, Suwan K, Want E, Bomalaski J, Szlosarek P, O'Neill K, Crook T, Syed N.

Cell Death Dis. 2018 Dec 13;9(12):1192. doi: 10.1038/s41419-018-1195-4.

5.

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.

Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK.

Cancer Chemother Pharmacol. 2018 Sep;82(3):429-440. doi: 10.1007/s00280-018-3635-3. Epub 2018 Jul 3.

PMID:
29971467
6.

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT.

Ann Oncol. 2018 Jun 1;29(6):1402-1408. doi: 10.1093/annonc/mdy101.

PMID:
29659672
7.

Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.

Gupta S, Sahu D, Bomalaski JS, Frank I, Boorjian SA, Thapa P, Cheville JC, Hansel DE.

Endocr Pathol. 2018 Sep;29(3):236-241. doi: 10.1007/s12022-018-9516-9.

PMID:
29453600
8.

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.

Tsai HJ, Jiang SS, Hung WC, Borthakur G, Lin SF, Pemmaraju N, Jabbour E, Bomalaski JS, Chen YP, Hsiao HH, Wang MC, Kuo CY, Chang H, Yeh SP, Cortes J, Chen LT, Chen TY.

Sci Rep. 2017 Sep 12;7(1):11253. doi: 10.1038/s41598-017-10542-4.

9.

A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.

Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, Glassman DC, Covington CM, Brenner R, Hollywood E, Barba A, Johnston A, Liu KC, Feng X, Capanu M, Abou-Alfa GK, O'Reilly EM.

Cancer. 2017 Dec 1;123(23):4556-4565. doi: 10.1002/cncr.30897. Epub 2017 Aug 18.

10.

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW.

J Clin Oncol. 2017 Jun 1;35(16):1778-1785. doi: 10.1200/JCO.2016.71.3230. Epub 2017 Apr 7.

11.

Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.

Kremer JC, Prudner BC, Lange SES, Bean GR, Schultze MB, Brashears CB, Radyk MD, Redlich N, Tzeng SC, Kami K, Shelton L, Li A, Morgan Z, Bomalaski JS, Tsukamoto T, McConathy J, Michel LS, Held JM, Van Tine BA.

Cell Rep. 2017 Jan 24;18(4):991-1004. doi: 10.1016/j.celrep.2016.12.077.

12.

Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase.

Sahu D, Gupta S, Hau AM, Nakashima K, Leivo MZ, Searles SC, Elson P, Bomalaski JS, Casteel DE, Boss GR, Hansel DE.

Am J Pathol. 2017 Jan;187(1):200-213. doi: 10.1016/j.ajpath.2016.09.004. Epub 2016 Dec 9.

13.

A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.

Bean GR, Kremer JC, Prudner BC, Schenone AD, Yao JC, Schultze MB, Chen DY, Tanas MR, Adkins DR, Bomalaski J, Rubin BP, Michel LS, Van Tine BA.

Cell Death Dis. 2016 Oct 13;7(10):e2406. doi: 10.1038/cddis.2016.232.

14.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemoine N, Sheaff MT, Rudd RM, Fennell D, Hackshaw A.

JAMA Oncol. 2017 Jan 1;3(1):58-66. doi: 10.1001/jamaoncol.2016.3049.

PMID:
27584578
15.

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.

Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, Anjos-Afonso F, Liapis K, Grantham M, Sohrabi F, Cavenagh J, Bomalaski JS, Gribben JG, Szlosarek PW, Bonnet D, Taussig DC.

Blood. 2015 Jun 25;125(26):4060-8. doi: 10.1182/blood-2014-10-608133. Epub 2015 Apr 20.

PMID:
25896651
16.

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.

Savaraj N, Wu C, Li YY, Wangpaichitr M, You M, Bomalaski J, He W, Kuo MT, Feun LG.

Oncotarget. 2015 Mar 20;6(8):6295-309.

17.

Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.

Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN Jr.

Clin Cancer Res. 2015 Jun 1;21(11):2480-6. doi: 10.1158/1078-0432.CCR-14-2610. Epub 2015 Mar 4.

18.

Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.

Cheon DJ, Walts AE, Beach JA, Lester J, Bomalaski JS, Walsh CS, Ruprecht Wiedemeyer W, Karlan BY, Orsulic S.

J Pathol Clin Res. 2014 Nov 5;1(1):41-53. doi: 10.1002/cjp2.4. eCollection 2015 Jan.

19.

Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.

Walts AE, Bomalaski JS, Ines D, Orsulic S.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1363-9. doi: 10.1007/s00432-014-1904-z. Epub 2014 Dec 30.

PMID:
25548129
20.

Granulocyte functions are independent of arginine availability.

Kapp K, Prüfer S, Michel CS, Habermeier A, Luckner-Minden C, Giese T, Bomalaski J, Langhans CD, Kropf P, Müller I, Closs EI, Radsak MP, Munder M.

J Leukoc Biol. 2014 Dec;96(6):1047-53. doi: 10.1189/jlb.3AB0214-082R. Epub 2014 Aug 7.

PMID:
25104794
21.

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.

Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW.

Cancer Res. 2014 Feb 1;74(3):896-907. doi: 10.1158/0008-5472.CAN-13-1702. Epub 2013 Nov 27.

22.

Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.

Stelter L, Fuchs S, Jungbluth AA, Ritter G, Longo VA, Zanzonico P, Raschzok N, Sauer IM, Bomalaski JS, Larson SM.

Mol Imaging Biol. 2013 Dec;15(6):768-75. doi: 10.1007/s11307-013-0655-6.

23.

Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.

Stelter L, Evans MJ, Jungbluth AA, Longo VA, Zanzonico P, Ritter G, Bomalaski JS, Old L, Larson SM.

Mol Imaging. 2013 Jan-Feb;12(1):67-73.

PMID:
23348793
24.

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.

Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O'Neil K, Roncaroli F, Crook T.

Cell Death Dis. 2013 Jan 17;4:e458. doi: 10.1038/cddis.2012.197.

25.

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.

Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, Bomalaski JS, Venhaus R, Pan L, Old LJ, Pavlick AC, Wolchok JD.

Invest New Drugs. 2013 Apr;31(2):425-34. doi: 10.1007/s10637-012-9862-2. Epub 2012 Aug 5.

26.

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.

Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, Cerio R, Gribben J, Lemoine N, Bomalaski J, Li CF, Joel S, Fitzgibbon J, Chen LT, Szlosarek PW.

Cell Death Dis. 2012 Jul 5;3:e342. doi: 10.1038/cddis.2012.83.

27.

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.

Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N.

Br J Cancer. 2012 Apr 24;106(9):1481-5. doi: 10.1038/bjc.2012.106.

28.

Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.

Stelter L, Evans MJ, Jungbluth AA, Zanzonico P, Ritter G, Ku T, Rosenfeld E, Bomalaski JS, Old L, Larson SM.

J Nucl Med. 2012 Feb;53(2):281-6. doi: 10.2967/jnumed.111.092973. Epub 2012 Jan 6.

29.

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.

Kelly MP, Jungbluth AA, Wu BW, Bomalaski J, Old LJ, Ritter G.

Br J Cancer. 2012 Jan 17;106(2):324-32. doi: 10.1038/bjc.2011.524. Epub 2011 Dec 1.

30.

Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.

Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G, Cremona F, Ensor CM, Holtzberg FW, Bomalaski JS, Clark MA, Curley SA, Orlando R, Scordino F, Korba BE.

J Gastroenterol Hepatol. 2007 Jan;22(1):86-91.

PMID:
17201887
31.

Concomitant activation of extracellular signal-regulated kinase and induction of COX-2 stimulates maximum prostaglandin E2 synthesis in human airway epithelial cells.

Petrovic N, Knight DA, Bomalaski JS, Thompson PJ, Misso NL.

Prostaglandins Other Lipid Mediat. 2006 Dec;81(3-4):126-35. Epub 2006 Oct 2.

PMID:
17085321
32.

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.

Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF.

J Clin Oncol. 2005 Oct 20;23(30):7660-8. Erratum in: J Clin Oncol. 2006 Aug 20;24(24):4047.

PMID:
16234528
33.

Phospholipase A2 activating protein induces tumor regression.

Goddard DH, Bomalaski JS, Clark MA.

Drug News Perspect. 1998 Mar;11(2):104-10.

PMID:
15616658
34.

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.

Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, Curley SA.

J Clin Oncol. 2004 May 15;22(10):1815-22.

PMID:
15143074
35.
36.

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.

Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA.

Cancer. 2004 Feb 15;100(4):826-33.

37.

Regression of hepatocellular cancer in a patient treated with arginine deiminase.

Curley SA, Bomalaski JS, Ensor CM, Holtsberg FW, Clark MA.

Hepatogastroenterology. 2003 Sep-Oct;50(53):1214-6.

PMID:
14571701
38.
39.

Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.

Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA.

J Rheumatol. 2002 Sep;29(9):1942-9.

PMID:
12233890
40.

Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production.

Dillon BJ, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA.

Med Sci Monit. 2002 Jul;8(7):BR248-53.

PMID:
12118186
42.

Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties.

Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA.

J Control Release. 2002 Apr 23;80(1-3):259-71.

PMID:
11943403
43.

Diagnosis and management of vulvar and vaginal intraepithelial neoplasia.

Cardosi RJ, Bomalaski JJ, Hoffman MS.

Obstet Gynecol Clin North Am. 2001 Dec;28(4):685-702. Review.

PMID:
11766145
44.

Mammography.

Bomalaski JJ, Tabano M, Hooper L, Fiorica J.

Curr Opin Obstet Gynecol. 2001 Feb;13(1):15-23. Review.

PMID:
11176228
45.
46.

Cholera toxin induces synthesis of phospholipase A2-activating protein.

Peterson JW, Saini SS, Dickey WD, Klimpel GR, Bomalaski JS, Clark MA, Xu XJ, Chopra AK.

Infect Immun. 1996 Jun;64(6):2137-43.

47.

Phospholipase A2-mediated inflammation induces regression of malignant gliomas.

Goddard DH, Bomalaski JS, Lipper S, Shorr RG, Clark MA.

Cancer Lett. 1996 Apr 19;102(1-2):1-6.

PMID:
8603356
48.

Clinical assessment of the 1987 American College of Rheumatology criteria for rheumatoid arthritis.

Levin RW, Park J, Ostrov B, Reginato A, Baker DG, Bomalaski JS, Borofsky M, Gardiner M, Leventhal L, Louthrenoo W, von Feldt J, Kolasinski S, Schumacher HR Jr.

Scand J Rheumatol. 1996;25(5):277-81.

PMID:
8921919
49.

Phospholipase A2-activating protein induces the synthesis of IL-1 and TNF in human monocytes.

Bomalaski JS, Ford T, Hudson AP, Clark MA.

J Immunol. 1995 Apr 15;154(8):4027-31.

PMID:
7706741
50.

Activation of mechanonociceptors by pro-inflammatory peptides melittin and PLAP peptide.

Cooper B, Bomalaski JS.

Exp Brain Res. 1994;100(1):18-28.

PMID:
7813648

Supplemental Content

Loading ...
Support Center